Press release
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
Conference Call and Webcast Today, August 7, 2023 at 4:30 p.m. ET PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":"\nConference Call and Webcast Today, August 7, 2023 at 4:30 p.m. ET\n\n\n PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023. The company is hosting a conference call today, Aug. 7, 2023, at 4:30 p.m. ET to discuss the results.\n\n\nWebcast and Conference Call and Details\n\n\nInvestors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of the call.\n\n\nFor analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIcd0f2b791a4f4cdd97a1c78e09086106. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.\n\n\nSelected Recent Events\n\n\n\nHosted a Research & Development Day to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiMTM) platform to a total of 20 clinical stage or marketed products in the year 2025. Key updates included:\n\n\nNew Phase 1 clinical data on ARO-RAGE showing a continued dose response in healthy volunteers with a single inhaled dose of 184 mg achieving mean knockdown of 90% and a maximum of 95% in bronchoalveolar lavage fluid (BALF)\n\n\n\nSerum sRAGE reductions in asthma patients consistent with effects seen in healthy volunteers at the 44 mg dose, the only dose level with results currently available in asthma patient cohorts\n\n\n\nTRiMTM platform for intrathecal administration for central nervous system (CNS) delivery demonstrates 90-95% dose-dependent mRNA knockdown in disease-relevant spinal cord and cortex brain regions in non-human primates\n\n\n\nTRiMTM platform for adipose tissue delivery achieved up to 98% knockdown and maintained greater than 85% knockdown over 31 weeks\n\n\n\nTRiMTM dimer platform for delivery to hepatocytes achieved equivalent or better knockdown of two separate target genes with longer duration than monomer mixture\n\n\n\n\n\n\nCompleted enrollment of the global PALISADE Phase 3 clinical trial evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome. The company anticipates that the pr...